U.K.-based pharmaceutical company raises guidance for 2014 after reporting higher-than-expected first-quarter profits, but stays quiet on takeover rumors.
via WSJ.com: US Business http://ift.tt/1hWKq27
via WSJ.com: US Business http://ift.tt/1hWKq27
Nessun commento:
Posta un commento